tiprankstipranks
Trending News
More News >
Teladoc (TDOC)
NYSE:TDOC
Advertisement

Teladoc (TDOC) AI Stock Analysis

Compare
12,011 Followers

Top Page

TDOC

Teladoc

(NYSE:TDOC)

Rating:56Neutral
Price Target:
$9.00
▲(9.76%Upside)
Teladoc's overall stock score reflects a mix of challenges and opportunities. The company faces profitability issues and valuation concerns, yet shows potential through positive technical indicators and strategic initiatives. The stable equity base and cash flow improvements provide a foundation for future growth, but macroeconomic challenges and revenue declines remain significant risks.
Positive Factors
Acquisitions
Teladoc’s recent acquisitions, Catapult and Uplift, provide optionality to drive higher revenue per member.
Market Expansion
Teladoc is adding insurance coverage, growing in international markets, and adding new pricing models/product enhancements.
Negative Factors
Consumer Spending
The slower MAU growth likely reflects a more cautious consumer spend environment, elevated CAC, and increasing competitive environment with in-network alternatives.
Enrollment Declines
Teladoc expects chronic care enrollment to decline sequentially due to a previously discussed contract loss.
Revenue Decline
Average revenue per US Integrated Care Member fell 8.6% sequentially and 8.0% year-over-year to $1.27.

Teladoc (TDOC) vs. SPDR S&P 500 ETF (SPY)

Teladoc Business Overview & Revenue Model

Company DescriptionTeladoc Health, Inc. (TDOC) is a global leader in virtual healthcare services, operating in the telemedicine and telehealth sectors. The company provides a broad spectrum of healthcare services, including on-demand remote medical care through mobile devices, the internet, video, and phone. Teladoc's core services encompass primary care, mental health support, dermatology, nutrition, and chronic condition management, aiming to provide convenient, affordable access to quality healthcare.
How the Company Makes MoneyTeladoc generates revenue through a combination of subscription fees and visit fees. Subscription fees are primarily derived from contracts with employers, health plans, and insurance providers, who pay Teladoc to offer its services to their members or employees. These contracts are typically based on a per-member-per-month fee structure. Additionally, Teladoc earns visit fees each time a member uses its services for a medical consultation. The company also benefits from strategic partnerships with healthcare providers and insurers, which expand its reach and increase its client base. Other revenue streams include licensing its technology platform to other healthcare providers and offering specialty services that cater to specific medical needs.

Teladoc Key Performance Indicators (KPIs)

Any
Any
US Integrated Care Members
US Integrated Care Members
Tracks the number of members enrolled in Teladoc's integrated care services in the US, indicating the company's reach and penetration in the domestic healthcare market.
Chart InsightsTeladoc's US Integrated Care Members have shown consistent growth, reaching over 102 million by Q1 2025. This growth aligns with the company's strategic focus on member engagement and international expansion, as highlighted in their earnings call. Despite challenges in other segments, such as BetterHelp, the Integrated Care segment remains a stable growth driver, supported by increased visit volumes and successful international partnerships. However, the anticipated flat to modest revenue growth in this segment suggests potential saturation or competitive pressures that investors should monitor.
Data provided by:Main Street Data

Teladoc Earnings Call Summary

Earnings Call Date:Jul 24, 2025
(Q1-2025)
|
% Change Since: 0.00%|
Next Earnings Date:Oct 22, 2025
Earnings Call Sentiment Neutral
The earnings call presented a mix of positive strategic developments such as the acquisition of UpLift, growth in the Integrated Care segment, and international success, but these were offset by financial challenges, including revenue decline, net losses, and macroeconomic concerns. The sentiment is balanced, reflecting both opportunities and challenges.
Q1-2025 Updates
Positive Updates
Acquisition of UpLift
Teladoc Health announced the acquisition of UpLift, a virtual mental health company, to enhance its BetterHelp segment. UpLift is an in-network provider to health plans covering over 100 million lives, which aligns with Teladoc's strategic priorities.
Integrated Care Segment Growth
The Integrated Care segment saw revenue of $389.5 million, a 3.3% increase over the prior year, driven by U.S. virtual visit volume increase of 7% and chronic care enrollment growth of 3%.
International Business Success
Teladoc's international business in the Integrated Care segment grew with revenue increasing in the mid-teens on a constant currency basis.
Recognition for Trustworthiness
Teladoc was named to Newsweek's Most Trustworthy Companies in America for 2025 and ranked number one in the healthcare and life sciences industry.
Negative Updates
Revenue Decline
First quarter consolidated revenue was $629.4 million, down 3% year-over-year. BetterHelp segment revenue decreased by 11% compared to the prior year.
Net Loss Per Share
Consolidated net loss per share was $0.53, compared to a net loss per share of $0.49 in the first quarter of 2024, including a non-cash goodwill impairment charge.
Challenges in BetterHelp Segment
BetterHelp's adjusted EBITDA margin decreased from 5.7% to 3.2%, and average paying users declined slightly. There were increased member churn rates noted.
Macroeconomic and Tariff Concerns
The broader economic environment and potential $5 million to $10 million tariff impact pose challenges, particularly with the fluidity of the situation.
Company Guidance
During the Teladoc Health First Quarter 2025 Earnings Call, significant guidance was provided concerning financial performance and strategic initiatives. The company reported consolidated revenue of $629.4 million, with adjusted EBITDA of $58.1 million, both at the higher end of guidance ranges. The BetterHelp segment saw a revenue of $239.9 million and an adjusted EBITDA margin of 3.2%. For full-year 2025, Teladoc expects revenue between $2.47 billion and $2.58 billion, with an adjusted EBITDA range of $263 million to $304 million. The recent acquisition of UpLift is anticipated to contribute approximately $10 million in incremental revenue in 2025, with potential increased member durations and conversion rates due to benefits coverage. The company is also focusing on technology improvements and international expansion to drive growth. Despite uncertainties in the macroeconomic environment, Teladoc emphasized its strategic priorities to expand access to virtual mental health services and leverage its scale in integrated care and BetterHelp segments.

Teladoc Financial Statement Overview

Summary
Teladoc's financial performance is marked by ongoing challenges in profitability, with negative net profit margins and fluctuating revenue growth. However, improvements in free cash flow and a stable equity base provide some positive outlooks.
Income Statement
45
Neutral
Teladoc has shown fluctuating revenue growth, with a decline from 2023 to the TTM period. The gross profit margin is stable at around 66-67%, but the net profit margin remains negative, indicating ongoing losses. EBIT and EBITDA margins are also negative, reflecting operational challenges.
Balance Sheet
55
Neutral
The debt-to-equity ratio is relatively high, suggesting considerable leverage, but the equity ratio demonstrates a stable equity base. The ROE remains negative due to continuous net losses, which indicates profitability concerns.
Cash Flow
60
Neutral
Free cash flow has been positive in the TTM period, showing signs of improvement. The operating cash flow to net income ratio is favorable, suggesting a good cash conversion from operations despite negative net income.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue2.57B2.60B2.41B2.03B1.09B
Gross Profit1.82B1.84B1.66B1.38B703.13M
EBITDA-587.01M154.00M-13.38B-84.67M-438.01M
Net Income-1.00B-220.37M-13.66B-428.79M-485.14M
Balance Sheet
Total Assets3.52B4.39B4.35B17.73B17.76B
Cash, Cash Equivalents and Short-Term Investments1.30B1.12B918.18M896.02M786.57M
Total Debt1.58B1.59B1.57B1.27B1.47B
Total Liabilities2.03B2.07B2.04B1.69B1.87B
Stockholders Equity1.49B2.33B2.31B16.05B15.88B
Cash Flow
Free Cash Flow282.89M193.67M16.53M130.06M-79.55M
Operating Cash Flow293.68M350.02M189.29M193.99M-53.51M
Investing Cash Flow-124.05M-156.35M-167.74M-72.98M-590.98M
Financing Cash Flow8.31M10.85M6.50M40.95M859.14M

Teladoc Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price8.20
Price Trends
50DMA
7.65
Positive
100DMA
7.74
Positive
200DMA
8.95
Negative
Market Momentum
MACD
0.17
Positive
RSI
52.30
Neutral
STOCH
55.51
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TDOC, the sentiment is Neutral. The current price of 8.2 is below the 20-day moving average (MA) of 8.33, above the 50-day MA of 7.65, and below the 200-day MA of 8.95, indicating a neutral trend. The MACD of 0.17 indicates Positive momentum. The RSI at 52.30 is Neutral, neither overbought nor oversold. The STOCH value of 55.51 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TDOC.

Teladoc Risk Analysis

Teladoc disclosed 57 risk factors in its most recent earnings report. Teladoc reported the most risks in the "Ability to Sell" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Teladoc Peers Comparison

Overall Rating
UnderperformOutperform
Sector (60)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
64
Neutral
$822.66M43.435.40%0.43%3.36%7.51%
60
Neutral
HK$17.07B6.10-7.44%2.88%11.55%-28.15%
59
Neutral
$241.26M-60.75%4.66%11.33%
58
Neutral
$1.10B-10.99%10.24%2.63%
58
Neutral
$281.89M-19.80%4.88%37.87%
56
Neutral
$1.44B-54.49%-2.54%-322.03%
52
Neutral
$135.80M-44.04%2.79%58.22%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
TDOC
Teladoc
8.20
-1.05
-11.35%
HSTM
HealthStream
26.95
-1.71
-5.97%
EVH
Evolent Health
9.35
-12.84
-57.86%
HCAT
Health Catalyst
3.85
-3.94
-50.58%
AMWL
American Well
8.70
0.35
4.19%
SOPH
SOPHiA GENETICS
3.61
-1.02
-22.03%

Teladoc Corporate Events

Private Placements and FinancingBusiness Operations and Strategy
Teladoc Secures $300M Credit Facility with JPMorgan
Positive
Jul 23, 2025

On July 17, 2025, Teladoc Health, Inc. entered into a credit agreement with JPMorgan Chase Bank, establishing a $300 million senior secured revolving credit facility to enhance financial and operational flexibility. The facility, which has a five-year term, is designed to support Teladoc’s strategic initiatives without immediate borrowing plans, and includes financial covenants to maintain leverage and interest coverage ratios.

The most recent analyst rating on (TDOC) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on Teladoc stock, see the TDOC Stock Forecast page.

Shareholder MeetingsBusiness Operations and Strategy
Teladoc Approves Key Proposals at Annual Meeting
Neutral
May 23, 2025

On May 22, 2025, Teladoc Health, Inc. held its Annual Meeting of Stockholders, where several key proposals were approved. Notably, the stockholders approved an amendment to the 2023 Incentive Award Plan, increasing the number of shares available for issuance by 6,850,000. Additionally, the election of directors and the ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, were confirmed. These decisions are expected to impact the company’s strategic direction and operational governance.

The most recent analyst rating on (TDOC) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on Teladoc stock, see the TDOC Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 24, 2025